https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-10 / Cancer Immunol. Immunother. 2009 Jul;58(7):1169-742009-04-10 00:00:002019-02-15 08:48:09Vaccination strategies in patients with renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Pancreas 2009 Apr;38(3):e69-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Pancreas 2009 Apr;38(3):e69-742009-04-01 00:00:002019-02-15 08:52:34A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-01 / Expert Opin Investig Drugs 2009 Apr;18(4):509-192009-04-01 00:00:002019-02-15 08:46:47DCVax-Brain and DC vaccines in the treatment of GBM
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-24 / Clin. Cancer Res. 2009 Apr;15(7):2531-402009-03-24 00:00:002019-02-15 08:49:29Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-11 / Blood 2009 May;113(21):5167-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-11 / Blood 2009 May;113(21):5167-752009-03-11 00:00:002019-02-15 08:44:19Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-05 / Vaccine 2009 May;27(25-26):3401-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-05 / Vaccine 2009 May;27(25-26):3401-42009-02-05 00:00:002019-02-15 08:44:21Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-03 / Cancer Res. 2009 Feb;69(4):1448-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-03 / Cancer Res. 2009 Feb;69(4):1448-582009-02-03 00:00:002019-02-15 08:51:31Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1667-732009-02-01 00:00:002019-02-15 08:50:59Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / Curr Pharm Biotechnol 2009 Feb;10(2):166-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / Curr Pharm Biotechnol 2009 Feb;10(2):166-842009-02-01 00:00:002019-02-15 08:44:29Targeting the immune system in cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-02-01 / J. Immunol. 2009 Feb;182(3):1449-59
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-02-01 / J. Immunol. 2009 Feb;182(3):1449-592009-02-01 00:00:002019-02-15 08:44:31Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway
